Canaccord Genuity Rates Zevra Therapeutics (ZVRA) buy

Canaccord Genuity reaffirms its buy rating for Zevra Therapeutics, setting a target price of $29, despite the stock trading at $12.55, a 131.08% upside from the current price.

By EarningsIQ Research Desk · Published Jun 13, 2026, 2:07 AM EDT · Updated Jun 17, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity rated Zevra Therapeutics, Inc. ($ZVRA) "buy" with a $29 price target on June 11, 2026.

Since the rating, $ZVRA is down 0.5% after 1 week, up 1.6% after 1 month and down 23.4% to date (from the $12.97 close on Jun 11, 2026).

ZVRA Zevra Therapeutics, Inc.

$9.94 +19.18% year to date

Daily close · Oct 16, 2026

Key Points

On June 11, 2026, Canaccord Genuity reiterated its buy rating on Zevra Therapeutics, Inc. (ZVRA) with a price target of $29.
Canaccord Genuity's $29 price target implies 131.08% upside from Zevra Therapeutics, Inc.'s ($ZVRA) current $12.55 share price.
Zevra's stock closed at $12.55, significantly lower than the new target, suggesting room for growth.
Analysts on Wall Street generally maintain a positive outlook on Zevra, with a consensus recommendation of strong buy and a mean price target of $25.

Get $ZVRA trade alerts by text

We text you when insiders, Congress or big funds trade $ZVRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Zevra Therapeutics, Inc. alert may contain errors. Disclosures

Canaccord Genuity's Reiterated Buy Rating

On June 11, 2026, Canaccord Genuity reiterated its buy rating on Zevra Therapeutics, Inc. (NASDAQ: ZVRA), setting a price target of $29. The stock was trading at $12.55 on the day of the announcement, showing a considerable gap between the current price and the target.

Comparing Analyst Ratings

This recent call from Canaccord Genuity aligns with a positively skewed sentiment on Wall Street. Other analysts have also expressed favorable views on Zevra. For instance, HC Wainwright & Co. reiterated its buy rating with a target of $26 on August 20, 2026, while Guggenheim maintained a buy rating with a revised target of $23 on August 7, 2026. Citizens Financial Group also stayed positive, maintaining a market outperform rating with a target of $28 on August 6, 2026. Overall, the average target from multiple analysts stands at $25, indicating strong confidence in the company’s future.

How Zevra Therapeutics, Inc. Stock Has Traded

Zevra Therapeutics' stock price of $12.55 is positioned above its 52-week low of $7.88 but remains below its 52-week high of $15.04. This price level may attract investor interest as it trades well below the analysts' price targets, reflecting potential upside according to Canaccord Genuity's assessment.

12-month forecast

$ZVRA price target

Zevra Therapeutics, Inc. daily closes and this analyst's $29 target. Not advice.

Recent Earnings

Zevra recently reported revenue of approximately $136.1 million, showing a year-over-year growth of about 53.3%. The company has a net margin of 42.8% and a return on equity of 34.8%, which indicates it is generating profits efficiently. The next earnings report is scheduled for November 4, 2026, which will likely provide further insights into its financial health and growth trajectory.

What Zevra Therapeutics, Inc. Does

Zevra Therapeutics focuses on developing treatments for rare diseases in the U.S. Its lead product, KP1077, is currently under Phase 3 clinical trials for idiopathic hypersomnia and narcolepsy, alongside other investigational products targeting various conditions. Given the unmet needs in these areas, the company's pipeline is crucial for its growth potential.

What's Ahead for Zevra Therapeutics, Inc.

As investors monitor Zevra's performance, they will be watching for the upcoming earnings report on November 4, 2026. Canaccord Genuity's recent rating reflects ongoing optimism about the company's potential growth in the biotechnology sector, and further updates may clarify its market position. Keep in mind that ratings like these from analysts are based on prior performance and may not indicate current market trends.